New Insights into Iron Metabolism and Deficiency

Chairpeople:

Angel de Francisco,¹ Kai-Uwe Eckardt²

Speakers:

Kai-Uwe Eckardt,² Tomas Ganz,³ Jolanta Małyszko⁴

1. Faculty of Medicine, Cantabria University, Santander, Spain
2. Department of Nephrology and Hypertension, University of Erlangen-Nürnberg, Erlangen, Germany
3. David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA
4. 2nd Department of Nephrology, Medical University Białystok, Białystok, Poland

Disclosure:

Prof Kai-Uwe Eckardt has received funding for the German Chronic Kidney Disease study from the German Ministry of Education and Research, and the Foundation for Preventative Medicine (Stiftung Präventivmedizin des KfH). He has also received funding from Amgen, Ardea, Bayer, Dicerna, FMC, Roche Diagnostics, and Vifor. Prof Tomas Ganz has received research grants from the National Institutes of Health, USA, and funding or other forms of support from Merganser Biotech, Silarus Pharma, Keryx Pharma, Vifor, and Intrinsic LifeSciences. Prof Jolanta Małyszko has received funding or other forms of support from Amgen, FMC, and Vifor Fresenius.

Acknowledgements:

Writing assistance was provided by Tabasum Mughal of ApotheCom, UK.

Support:

The symposium was sponsored by Vifor Fresenius Medical Care Renal Pharma. Authors received honoraria for preparation and delivery of their presentations. The views and opinions expressed are those of the authors and not necessarily of Vifor Fresenius Medical Care Renal Pharma.

Citation:

EMJ Nephrol. 2016;4[1]:36-41. DOI/10.33590/emjnephrol/10312295. https://doi.org/10.33590/emjnephrol/10312295.

Keywords:

ERA-EDTA 2016

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.